Leustatin (Cladribine)

Cladribine enters lymphocytes and is phosphorylated to an active triphosphate that incorporates into DNA. This blocks DNA synthesis and triggers programmed cell death, selectively depleting malignant B‑cells while sparing most other cell types.

The dosing regimen for Leustatin is individualized and determined by the treating physician based on disease severity, patient weight, renal function, and other clinical factors. The prescriber sets the exact dose and infusion schedule.

Safety data for cladribine in pregnancy and lactation are limited. It is generally avoided unless the potential therapeutic benefit justifies the potential risk to the fetus or infant. Women of child‑bearing potential should use effective contraception during treatment.

To request Leustatin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and necessary import documentation.

Leustatin (cladribine) belongs to the purine nucleoside analog class, similar to fludarabine. Compared with fludarabine, cladribine has a longer intracellular half‑life and may achieve deeper lymphocyte depletion, but both share comparable myelosuppressive profiles. Choice depends on physician assessment of efficacy, tolerability and patient‑specific factors.

Leustatin must be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. During transport, maintain the cold‑chain to preserve product stability.

Leustatin is given as an intravenous infusion. The solution is diluted according to the prescribing information and infused over a period defined by the treating physician, typically ranging from 30 minutes to several hours, with monitoring for infusion‑related reactions.

The most serious risks include severe neutropenia leading to life‑threatening infections, opportunistic infections, tumor lysis syndrome, autoimmune hemolysis, and hepatic toxicity. Patients should be monitored closely for signs of infection, liver enzyme changes, and blood count abnormalities throughout therapy.

Leustatin is contraindicated in patients with active uncontrolled infections, known hypersensitivity to cladribine or any excipients, and those who have received live vaccines within four weeks of treatment. Caution is also advised for individuals with severe renal impairment or pre‑existing severe bone‑marrow suppression.